Abstract
The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Current Drug Targets
Title: Natural History of Ulcerative Colitis: Current Knowledge
Volume: 12 Issue: 10
Author(s): Lajos Sandor Kiss and Peter Laszlo Lakatos
Affiliation:
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Abstract: The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Export Options
About this article
Cite this article as:
Sandor Kiss Lajos and Laszlo Lakatos Peter, Natural History of Ulcerative Colitis: Current Knowledge, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818117
DOI https://dx.doi.org/10.2174/138945011796818117 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
Current Genomics Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma
Current Drug Targets Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Prognosis, Significance and Positive Correlation of Rab1A and p-S6K/Gli1 Expression in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Current Drug Targets Has Selenium a Chemopreventive Effect on Hepatocellular Carcinoma?
Mini-Reviews in Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma
Current Molecular Pharmacology Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anticarcinogenic Effects of Capsaicin-Loaded Nanoparticles on In vitro Hepatocellular Carcinoma
Current Chemical Biology Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews